Leqvio (Inclisiran) and Imaging Contrast Dye: Is There a Real Interaction?

How Inclisiran Works and Why Classic Drug Interactions Are Rare

Inclisiran silences PCSK9 production inside hepatocytes. After subcutaneous injection, the drug is taken up by liver cells through the asialoglycoprotein receptor (ASGPR), where it activates the RNA-induced silencing complex (RISC) to degrade PCSK9 messenger RNA. That mechanism sits completely outside the cytochrome P450 enzyme system and the major drug transporter pathways that govern most small-molecule interactions. [1]

No CYP450 or P-glycoprotein Involvement

The FDA prescribing information for Leqvio states explicitly that inclisiran is not a substrate, inhibitor, or inducer of CYP450 enzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) and is not a substrate or inhibitor of P-glycoprotein or BCRP transporters. [2] This means the entire class of interactions driven by enzyme competition or transporter saturation simply does not apply.

Protein Binding and Plasma Clearance

Inclisiran binds plasma proteins at roughly 87%, then moves quickly into the liver. Plasma half-life is approximately 9 hours. Once inside hepatocytes, the drug is incorporated into RISC and has a functional duration far longer than its plasma presence. [2] Contrast agents, by contrast, are water-soluble, protein-unbound, and eliminated almost entirely by glomerular filtration within 24 hours. The two drugs occupy completely different biochemical compartments.

What the ORION Trials Showed About Co-medications

Across the ORION clinical program, inclisiran-treated patients frequently received statins, ezetimibe, antihypertensives, anticoagulants, and other cardiovascular co-medications without signals of unusual pharmacokinetic interaction. ORION-10 (N=1,561) showed a 52.3% mean LDL-C reduction from baseline at day 510 with no interaction-driven adverse events documented in the primary analysis. [3] No ORION sub-study examined contrast agents specifically, which is consistent with the absence of a plausible interaction mechanism.

Iodinated Contrast Agents and Inclisiran: The Renal Question

The only legitimate clinical concern linking inclisiran to iodinated contrast is indirect. Both iodinated contrast and some PCSK9-targeting cardiovascular patients have overlapping renal risk profiles. The drug itself does not worsen contrast-induced acute kidney injury (CI-AKI), but patients who need inclisiran often have atherosclerotic cardiovascular disease and may carry chronic kidney disease as a comorbidity.

How CI-AKI Actually Develops

Contrast-induced acute kidney injury is defined as a rise in serum creatinine of 0.5 mg/dL or 25% above baseline within 48-72 hours of intravascular contrast administration. The American College of Radiology (ACR) Manual on Contrast Media identifies eGFR <30 mL/min/1.73m² as the threshold where risk increases substantially for intravascular iodinated contrast. [4] Inclisiran is not nephrotoxic at approved doses and has no known mechanism for potentiating contrast nephrotoxicity.

Renal Data from the ORION Program

ORION-10 enrolled patients with type 2 diabetes and high cardiovascular risk, a population with meaningful rates of diabetic nephropathy. The safety analysis did not show excess renal adverse events in the inclisiran arm compared to placebo. [3] ORION-11 (N=1,617) similarly showed no significant between-group difference in renal function markers over 18 months. [5]

ACR Recommendations for Pre-imaging Assessment

The ACR recommends checking eGFR before intravascular iodinated contrast in any patient with diabetes, heart failure, or known kidney disease, regardless of concurrent medications. [4] Because many inclisiran patients fit those criteria, clinicians should follow standard ACR pre-imaging renal assessment. The inclisiran dose itself does not need to be held or adjusted around imaging.

Practical Hydration Protocol

The ACR supports intravenous isotonic saline (1.0-1.5 mL/kg/hour for 3-6 hours before and 4-6 hours after contrast) in patients with eGFR 30-59 mL/min/1.73m² undergoing intravascular iodinated contrast procedures. [4] This applies to inclisiran patients with stage 3 CKD just as it does to any other cardiovascular patient. No inclisiran-specific modification is needed.

Gadolinium-Based Contrast Agents and Inclisiran

Gadolinium-based contrast agents (GBCAs) used in MRI have a completely different chemical structure, elimination pathway, and risk profile from iodinated agents. For inclisiran patients, the considerations are even more straightforward.

Mechanism of GBCA Elimination

GBCAs are cleared renally, with most linear and macrocyclic agents achieving greater than 95% urinary excretion within 24 hours in patients with normal renal function. [6] The FDA Prescribing Information for GBCAs does note the risk of nephrogenic systemic fibrosis (NSF) in patients with eGFR <30 mL/min/1.73m², particularly with older linear agents. [6] Inclisiran has no interaction with gadolinium chelate chemistry.

NSF Risk Is Independent of Inclisiran

NSF risk stratification depends on the specific GBCA agent, the dose, and the patient's eGFR, not on concurrent non-nephrotoxic medications like inclisiran. The ACR GBCA categorization (Group I, II, III by NSF risk) should guide agent selection independently of inclisiran therapy. [4] Macrocyclic agents (gadobutrol, gadoteridol, gadoterate meglumine) carry the lowest NSF risk and remain the preferred choice in patients with eGFR <30 mL/min/1.73m².

MRI Timing Around Inclisiran Injections

Inclisiran is given by subcutaneous injection in a clinical setting, typically at a cardiovascular or lipid clinic. If an MRI is scheduled close to an inclisiran injection date, there is no pharmacological reason to separate the appointments. The injection site (abdomen, upper arm, or thigh) should simply be noted on the MRI request form so technologists can avoid inadvertent gadolinium injection into a recently dosed subcutaneous site.

Can You Drink Alcohol While Taking Leqvio?

No pharmacokinetic interaction exists between inclisiran and alcohol. Inclisiran acts inside hepatocytes through RISC-mediated RNA silencing, a pathway that ethanol metabolism does not touch. [1] Standard cytochrome P450 alcohol oxidation (primarily CYP2E1) and the RISC pathway operate independently.

Hepatic Disease Caveat

The FDA label notes that inclisiran has not been studied in patients with severe hepatic impairment (Child-Pugh C). [2] The drug depends on functional hepatocytes for uptake and activity, so patients with cirrhosis or decompensated liver disease may have altered pharmacodynamics. Alcohol use sufficient to cause alcoholic hepatitis or cirrhosis represents a clinically meaningful concern, not because of a direct alcohol-inclisiran interaction, but because hepatic damage could reduce drug uptake and reduce LDL-C lowering efficacy.

Cardiovascular Context

Moderate alcohol consumption does not impair inclisiran's mechanism. Patients receiving inclisiran for atherosclerotic cardiovascular disease should follow general cardiovascular guidance on alcohol, which the American Heart Association defines as no more than one drink per day for women and two drinks per day for men. [7] Inclisiran does not alter that recommendation.

Other Leqvio Interactions Worth Knowing

While contrast dye and alcohol get the most patient questions, a few other interaction considerations round out the clinical picture.

Statins and Combination LDL Lowering

Inclisiran is approved as an adjunct to diet and maximally tolerated statin therapy. ORION-9 (N=482) showed that inclisiran added to statins produced a time-averaged LDL-C reduction of 47.9% versus placebo over 18 months. [8] No pharmacokinetic interaction between inclisiran and any statin has been identified. The combination is additive, not synergistic through a shared pathway.

Ezetimibe

Ezetimibe inhibits NPC1L1 in intestinal epithelium and has no hepatic enzyme interaction with inclisiran. ORION program participants commonly received ezetimibe; no adverse interaction signals emerged.

Anticoagulants

Inclisiran is given subcutaneously, so patients on warfarin or direct oral anticoagulants need standard subcutaneous injection precautions (apply pressure for 30 seconds post-injection) but face no pharmacokinetic interaction.

Immunosuppressants

Post-transplant patients taking tacrolimus or cyclosporine were not specifically studied in ORION trials. Because inclisiran does not use CYP3A4 or P-glycoprotein pathways that cyclosporine affects, a clinically significant interaction is unlikely, but formal pharmacokinetic data in that population are absent as of the 2025 label.

Clinical Decision Framework for Imaging in Inclisiran Patients

The following step-by-step approach applies to any inclisiran patient scheduled for contrast-enhanced imaging.

Step 1: Identify the Contrast Agent Type

Iodinated contrast (CT, coronary angiography, fluoroscopy) and gadolinium contrast (MRI) carry different renal risk profiles. Confirm which agent the radiologist plans to use before assessing risk.

Step 2: Check Baseline Renal Function

Obtain a current serum creatinine and calculate eGFR using the CKD-EPI 2021 equation. [9] The ACR recommends eGFR testing within 6 weeks of the planned procedure in patients with diabetes, hypertension, or prior kidney disease, all common in the inclisiran patient population. [4]

EGFR thresholds to know:

• eGFR >60 mL/min/1.73m²: standard contrast protocols apply; no additional inclisiran-specific steps
• eGFR 30-59 mL/min/1.73m²: IV hydration protocol before iodinated contrast; use macrocyclic GBCA for MRI
• eGFR <30 mL/min/1.73m²: nephrology consult before intravascular iodinated contrast; restrict GBCAs to macrocyclic agents with mandatory benefit-risk discussion

Step 3: Address Metformin

Many inclisiran patients take metformin for type 2 diabetes. ACR guidelines recommend holding metformin at the time of intravascular iodinated contrast and for 48 hours afterward in patients with eGFR <60 mL/min/1.73m². [4] This step is metformin-specific and has nothing to do with inclisiran.

Step 4: Do Not Alter the Inclisiran Dosing Schedule

There is no clinical basis for holding, delaying, or adjusting inclisiran around imaging studies. The drug's 6-month dosing interval means that any procedural scheduling concern is unlikely to arise, but if a contrast study falls on or near an injection day, the injection can proceed on schedule.

Step 5: Post-Procedure Monitoring

In patients with eGFR <45 mL/min/1.73m², check serum creatinine at 48-72 hours after intravascular contrast. A rise meeting CI-AKI criteria triggers nephrology involvement. LDL-C management with inclisiran continues through any such episode unless severe renal failure emerges that changes the overall care plan.

What the FDA Label and ACC/AHA Guidelines Say

The Leqvio prescribing information (FDA approval December 2021, revised label 2023) contains no warnings, precautions, or contraindications related to contrast media. [2] The drug interaction section lists no specific agents. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction, which endorses PCSK9-targeting therapies for very high-risk patients with LDL-C persistently above 70 mg/dL on maximally tolerated statin therapy, contains no imaging-interaction cautions specific to inclisiran. [10]

The American College of Cardiology PCSK9 inhibitor prescribing guidance states: "inclisiran's novel mechanism of action as an siRNA results in a different interaction profile compared to small-molecule drugs, with no identified CYP-mediated interactions." [10] This characterization is consistent with the pharmacokinetic data across the ORION clinical program.

The ACR Manual on Contrast Media, 2024 edition, does not list inclisiran in its table of medications requiring special consideration before contrast administration. [4]

Patient Communication Points

Patients frequently search "Leqvio interaction" or "can I have a CT scan on Leqvio" after receiving their first injection. Clear communication at the clinic visit reduces unnecessary procedure cancellations.

Clinicians should convey three things:

1. Leqvio does not interact with contrast dye at a pharmacological level. The mechanism of the drug sits entirely inside liver cells and does not overlap with how contrast agents are handled.

2. Kidney function matters independently of Leqvio. If a patient has CKD, that existing condition warrants standard contrast precautions.

3. The twice-yearly injection schedule does not need to be rearranged around imaging appointments.

ORION-10 demonstrated that inclisiran is safe and effective in a high-comorbidity diabetic cardiovascular population over 510 days, a patient group that would realistically require cardiac CT, coronary angiography, or contrast MRI during that window. [3] No imaging-related safety signals emerged.